Overview

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide
Hypoglycemic Agents
Insulin
Insulin, Globin Zinc